Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other Working Capital Changes (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Other Working Capital Changes for 16 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes fell 8.72% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$367000.0 through Dec 2025, down 312.36% year-over-year, with the annual reading at -$367000.0 for FY2025, 312.36% down from the prior year.
  • Other Working Capital Changes hit $1.4 million in Q4 2025 for Ironwood Pharmaceuticals, up from -$2.2 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $3.7 million in Q1 2023 to a low of -$7.7 million in Q3 2023.
  • Historically, Other Working Capital Changes has averaged -$165200.0 across 5 years, with a median of -$32000.0 in 2021.
  • Biggest five-year swings in Other Working Capital Changes: crashed 867.21% in 2021 and later skyrocketed 8253.33% in 2023.
  • Year by year, Other Working Capital Changes stood at $1.4 million in 2021, then crashed by 223.59% to -$1.8 million in 2022, then soared by 202.74% to $1.8 million in 2023, then dropped by 15.18% to $1.5 million in 2024, then fell by 8.72% to $1.4 million in 2025.
  • Business Quant data shows Other Working Capital Changes for IRWD at $1.4 million in Q4 2025, -$2.2 million in Q3 2025, and $612000.0 in Q2 2025.